Research and Development (R&D)

Overview

The Company’s R&D strengths are in developing intellectual property in non-infringing processes and resolving complex chemistry challenges.KIRBI Life Sciencesis in the process of developing new drug delivery systems, new dosage formulations, and applying new technology for better processes.

The R&D Center, in Pune covers over 13,000 sq.m, and provides a nurturing environment to a multi-disciplinary team of over 700 scientists striving for excellence.

The Centre meets cGLP requirements, and is focused on the areas of organic synthesis, analytical research, dosage form development, pharmacology, bio-equivalence studies and drug delivery systems.

The instrumentation and analytical knowledge base at the Centre facilitate:

Complete impurity profiling in all products developed.
Development of analytical methods and specifications from raw materials, to non-compendial finished products.
In-house synthesis of reagents for analysing organolithiums and noble metals.
Accelerated and real-time stability studies.

This reflects the Company’s commitment towards developing innovative technologies and creating a knowledge base in chemical synthesis, high quality generic formulations and development of drug delivery systems.

KIRBI LIFE SCIENCES quality policy is mandated and supported by the Executive Management and coordinated by an independent Quality Assurance (QA) Department.

The Centre is capable of developing, scaling up and commercializing various dosage forms spread across tablets, capsules, soft gels, oral liquids, injectables (solutions, suspensions, lyophilized, etc.), and ophthalmic (three piece and BFS) and nasal delivery systems.The focus is to develop products for the US and EU followed by other international markets, including specialized markets like Japan.We can develop complex in-vitro analytical as well as bio- analytical methods for various molecules including extremely potent drug combinations to support the formulation development team.The R&D Centre has developed products and filed more than 200 ANDA’s, around 124 EU Dossiers for products and hundreds of Dossiers in other countries including Brazil, South Africa, Australia and China.The product range covers various pharmacological categories with special focus on anti-retroviral, anti-biotic, CNS and CVS drugs.